81 related articles for article (PubMed ID: 10453723)
1. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status.
Borbé R; Rieger J; Weller M
Cancer Chemother Pharmacol; 1999; 44(3):217-27. PubMed ID: 10453723
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
3. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.
Roth W; Wagenknecht B; Grimmel C; Dichgans J; Weller M
Br J Cancer; 1998; 77(3):404-11. PubMed ID: 9472635
[TBL] [Abstract][Full Text] [Related]
4. Topotecan-based combination chemotherapy for human malignant glioma.
Schmidt F; Schuster M; Streffer J; Schabet M; Weller M
Anticancer Res; 1999; 19(2A):1217-21. PubMed ID: 10368678
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
[TBL] [Abstract][Full Text] [Related]
6. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
7. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
8. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
9. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.
Das GC; Holiday D; Gallardo R; Haas C
Cancer Lett; 2001 Apr; 165(2):147-53. PubMed ID: 11275363
[TBL] [Abstract][Full Text] [Related]
10. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
[TBL] [Abstract][Full Text] [Related]
11. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
Janss AJ; Levow C; Bernhard EJ; Muschel RJ; McKenna WG; Sutton L; Phillips PC
Exp Cell Res; 1998 Aug; 243(1):29-38. PubMed ID: 9716446
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer.
Rieger J; Ständer M; Löschmann PA; Heneka M; Dichgans J; Klockgether T; Weller M
Oncogene; 1998 Nov; 17(18):2323-32. PubMed ID: 9811463
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Winter S; Weller M
Eur J Pharmacol; 2000 Jun; 398(2):177-83. PubMed ID: 10854828
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay.
Powell SN; DeFrank JS; Connell P; Eogan M; Preffer F; Dombkowski D; Tang W; Friend S
Cancer Res; 1995 Apr; 55(8):1643-8. PubMed ID: 7712468
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Naumann U; Durka S; Weller M
Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
[TBL] [Abstract][Full Text] [Related]
16. Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation.
Ito H; Kanzawa T; Kondo S; Kondo Y
Int J Oncol; 2005 Mar; 26(3):589-96. PubMed ID: 15703812
[TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.
Roth W; Fontana A; Trepel M; Reed JC; Dichgans J; Weller M
Cancer Immunol Immunother; 1997 Mar; 44(1):55-63. PubMed ID: 9111585
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
20. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
